The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma.
Overview
- Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
- Fudan University – Dr. Kong Joint Research Center for Sports Medicine and Health Footwear, Fudan University Institute of Sports Medicine (Jinqiao Laboratory), Shanghai, China
- Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Acupuncture and Massage College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, China International Neuroscience Institute (CHINA-INI), National Medical Center for Neurological Disorders, Beijing, China
- Institute of Literature in Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
Abstract
Introduction: Glioma is a common primary solid brain tumor with high incidence and poor prognosis. Biochanin A (bioA), an active component of traditional Chinese medicine, has potential therapeutic effects on it, but its mechanism remains unclear. This study aimed to clarify its mechanism via a multi-omics strategy.
Methods: A multi-omics integration approach was adopted, which combined single-cell RNA sequencing, in vitro experiments, the construction of a Glutathione S-transferase P1 (GSTP1)-based prognostic model, and analyses of immune infiltration and drug sensitivity to evaluate its clinical value.
Results: C2 CENPF⁺ tumor cells were specifically expressed in recurrent gliomas and associated with the bioA pathway. GSTP1 was the key target gene of bioA; its high expression was related to poor prognosis, and its knockout could inhibit glioma progression. The GSTP1-based prognostic model had excellent predictive efficiency.
Discussion: BioA may exert anti-glioma effects by regulating GSTP1, providing theoretical support for its clinical application and a new therapeutic target for glioma.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data, not to its authors' code: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE182109, at NCBI GEO; found in the text, “ScRNA-seq data”
Data availability statement
The original contributions presented in the study are included in the article/
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 29 September 2026: the first record
Recorded: type, language, journal, volume, pages, dates, 10 authors, 7 keywords, 11 MeSH terms, 87 references.
Cite
This paper
Chai, D., Xi, M., Gao, L., Sun, L., Kong, D., Zhu, Y., Zhang, J., Cai, Q., Xiao, X., & Wang, C. (2026). The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma. Frontiers in immunology, 17, 1780159. https://
BibTeX
@article{chai2026therape
author = {Chai, Dan and Xi, Mengran and Gao, Lu and Sun, Lei and Kong, Desong and Zhu, Yujie and Zhang, Jinghua and Cai, Qiang and Xiao, Xinru and Wang, Changqing},
title = {{The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma}},
journal = {Frontiers in immunology},
year = {2026},
month = apr,
volume = {17},
pages = {1780159},
publisher = {Frontiers Media SA},
issn = {1664-3224},
doi = {10.3389/
url = {https://
pmid = {42093975},
pmcid = {PMC13139340}
}
RIS
TY - JOUR
AU - Chai, Dan
AU - Xi, Mengran
AU - Gao, Lu
AU - Sun, Lei
AU - Kong, Desong
AU - Zhu, Yujie
AU - Zhang, Jinghua
AU - Cai, Qiang
AU - Xiao, Xinru
AU - Wang, Changqing
TI - The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma
T2 - Frontiers in immunology
J2 - Front Immunol
PY - 2026
DA - 2026/
VL - 17
SP - 1780159
SN - 1664-3224
PB - Frontiers Media SA
DO - 10.3389/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3389/
"type": "article-journal",
"title": "The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma",
"container-title": "Frontiers in immunology",
"author": [
{
"family": "Chai",
"given": "Dan"
},
{
"family": "Xi",
"given": "Mengran"
},
{
"family": "Gao",
"given": "Lu"
},
{
"family": "Sun",
"given": "Lei"
},
{
"family": "Kong",
"given": "Desong"
},
{
"family": "Zhu",
"given": "Yujie"
},
{
"family": "Zhang",
"given": "Jinghua"
},
{
"family": "Cai",
"given": "Qiang"
},
{
"family": "Xiao",
"given": "Xinru"
},
{
"family": "Wang",
"given": "Changqing"
}
],
"container-title-short":
"volume": "17",
"page": "1780159",
"DOI": "10.3389/
"PMID": "42093975",
"PMCID": "PMC13139340",
"ISSN": "1664-3224",
"publisher": "Frontiers Media SA",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
21
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1016/j.isci.2026.115982 [code]
- Multi-omics profiling-derived signature links cellular ecosystem to glioblastoma prognosis.Journal: iScienceIn common: NCBI GEO GSE182109, genetics / omics, other condition
- [2] doi:10.3389/fonc.2026.1742452
- SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration.Journal: Frontiers in oncologyIn common: NCBI GEO GSE182109, genetics / omics, other condition
- [3] doi:10.32604/or.2026.079221
- Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target.Journal: Oncology researchIn common: genetics / omics, other condition, 2 references
- [4] doi:10.1080/17501911.2026.2691031
- Promoter methylation-associated brain-enriched long noncoding RNAs in glioblastoma: a multi-cohort public epigenomic re-analysis.Journal: EpigenomicsIn common: genetics / omics, other condition, 2 references
- [5] doi:10.1186/s13024-026-00946-0
- Insulin resistance alters cortical inhibitory neurons and microglia to exacerbate Alzheimer's knock-in mouse phenotypes.Journal: Molecular neurodegenerationIn common: genetics / omics, other condition, 2 references
- [6] doi:10.1038/s41586-026-10641-1 [code]
- Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.Journal: NatureIn common: other condition, 2 references
- [7] doi:10.1038/s41467-026-74058-0
- IQGAP3 bridges matrix stiffness with glioma stem cell maintenance and radioresistance by stabilizing SOX2.Journal: Nature communicationsIn common: other condition, 2 references
- [8] doi:10.1111/jcmm.71154
- Mitophagy-Oxidative Stress Molecular Subtypes Define an Immunosuppressive Ecosystem and Vulnerabilities in Glioblastoma.Journal: Journal of cellular and molecular medicineIn common: genetics / omics, other condition, 2 references
- [9] doi:10.3389/fonc.2026.1834400
- BrainFusionNet: an attention-augmented deep convolutional framework with hybrid loss optimisation and test-time augmentation for multi-class brain tumour detection in magnetic resonance images.Journal: Frontiers in oncologyIn common: other condition, 2 references
- [10] doi:10.1007/s12311-026-02006-1 [code]
- Innovative 3D-Image Analysis of Cerebellar Vascularization Highlights Angiogenic Gene Dysregulations in a Murine Model of Apnea of Prematurity.Journal: Cerebellum (London, England)In common: genetics / omics, 2 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.
Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.